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BRIEF DEFINITIVE REPORT
        MicroRNAs belong to a class of small noncod-
ing RNAs of     21 nt that control the expression 
of many genes (  1, 2  ). MicroRNAs are prefer-
entially transcribed by RNA polymerase II and 
can be derived from individual microRNA 
genes, introns of protein-coding genes, or poly-
cistronic transcripts. They are fi  rst transcribed 
as primary microRNAs (pri-microRNAs) that 
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  Most chromosomal translocations in myelodysplastic syndromes (MDS) and acute myeloid 
leukemia (AML) involve oncogenes that are either up-regulated or form part of new 
chimeric genes. The t(2;11)(p21;q23) translocation has been cloned in 19 cases of MDS 
and AML. In addition to this, we have shown that this translocation is associated with a 
strong up-regulation of miR-125b (from 6- to 90-fold). In vitro experiments revealed 
that miR-125b was able to interfere with primary human CD34  +   cell differentiation, and 
also inhibited terminal (monocytic and granulocytic) differentiation in HL60 and NB4 
leukemic cell lines. Therefore, miR-125b up-regulation may represent a new mechanism of 
myeloid cell transformation, and myeloid neoplasms carrying the t(2;11) translocation 
defi  ne a new clinicopathological entity. 
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tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
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translated region with the let-7 target sites. This impairs the 
repression by let-7 and leads to overexpression of HMGA2 
(  10  ). To the best of our knowledge, there is no paper men-
tioning chromosomal translocations leading to up-regulation 
of microRNAs in myelodysplastic syndromes (MDS) and 
acute myeloid leukemia (AML). 
  Chromosomal translocations are frequent in MDS and 
AML, and to date only rare abnormalities remain unchar-
acterized. Among them, the t(2;11)(p21;q23) chromosomal 
translocation is a rare event, although regularly reported 
(http://atlasgeneticsoncology.org) and specifi  cally observed in 
patients with MDS and AML. In some cases, the translocation is 
isolated, suggesting that it could be the cause of deregulation 
of genes particularly relevant in myeloid cell transformation. 
Thus, we collected a series of 19 cases of AML or MDS 
carrying the t(2;11)(p21;q23) translocation. This translo-
cation entailed an elevated expression of the microRNA 
miR-125b-1. In vitro transfections of miR-125b blocked 
the diff  erentiation of leukemic cell lines upon chemical treat-
ment. This property may account for the diff  erentiation 
blockage observed in leukemic cells in vivo. 
    RESULTS AND DISCUSSION   
  The t(2;11)(p21;q23) chromosomal translocation 
is a clinicopathological entity 
  The t(2;11)(p21;q23) chromosomal translocation was found 
in 19 patients with AML (  n   = 10) or MDS (  n   = 9;   Fig. 1 B  ; 
correspond to capped and polyadenylated transcripts of 
    1,000 nt. Pri-microRNAs are processed in the nucleus by 
the RNase Drosha into 70  –  80-nt, hairpin-shaped precursors, 
called pre-microRNAs (  1, 2  ). They are then exported in the 
cytoplasm by exportin5, cleaved into mature microRNAs 
(21 nt) by the RNase III endonuclease Dicer, and incorporated 
in the RNA-induced silencing complex (  1, 2  ). If the sequence 
alignment is perfect, the duplex microRNA  –  mRNA leads to 
degradation of the mRNA. If the alignment is incomplete, 
translation of the target mRNA is inhibited, but its stability is 
not aff  ected (  1  ). 
  Because microRNAs are involved in the regulation of 
many genes, they are suggested to control fundamental pro-
cesses, such as diff  erentiation, proliferation, and apoptosis. 
The disruption of their expression is now associated with sev-
eral human diseases, including cancers (  3  –  6  ). More than half 
of microRNAs are located at fragile sites and genomic regions 
implicated in cancer (  7  ). A few reports have described chro-
mosomal translocations that involve microRNAs (  7, 8  ). The 
t(8;17)(q24;q22) translocation fuses miR-142 to the   c-MYC   
oncogene and leads to overexpression of   c-MYC   in acute pro-
lymphocytic leukemia (  8, 9  ). Recent studies have shown that 
let-7 multiple target sites were located on the 3     untranslated 
region of   HMGA2   (  10  ). This is an example of suppression of 
an oncogene by a tumor-suppressive microRNA (  10  ). One 
mechanism of oncogene activation is the occurrence of chro-
mosomal translocations that eliminate the oncogene  ’  s 3     un-
    Figure 1.         Identifi  cation of the breakpoints on chromosome 11.   (A) Mapping of the BAC and fosmid probes on the breakpoint area and positions 
of the several mRNAs and microRNAs in this region. Vertical arrows show the exact position of the breakpoints for four patients obtained by LDI-PCR. 
(B) FISH showing chromosome painting of the t(2;11)(p21;q23) translocation in P1. Chromosome 2 is stained in green (biotin-streptavidin-FITC), and 
chromosome 11 is stained in red (digoxigenin-anti-dig-Rhodamine). (C) FISH with RP11-382J20 (green), as illustrated in A. The second BAC (red) is RP11-
142I2 located at 11q23. Note that RP11-382J20 is split (P1). Of note, this BAC is split in 16 out of 19 patients (Table S1, available at http://www.jem.org/
cgi/content/full/jem.20080285/DC1). (D) FISH with fosmid G248P85412D12 (green), as illustrated in A, and RP11-391M15 (red) mapping on chromosome 
2p21 (P12). This fosmid is split in three patients (Table S1).     JEM VOL. 205, October 27, 2008  2501
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gave a split signal on both chromosomes, meaning that the 
breakpoint was within this area (on an interval of     150 kb; 
  Fig. 1 C   and Table S2). To reduce this interval, we used 
fosmids (40 kb), which enabled us to shorten the breakpoint 
region on chromosome 11 to 40 kb (  Fig. 1 D   and Table S2). 
The same strategy was adopted for chromosome 2 and allowed 
us to defi  ne an interval of 300 kb (Table S2 and Fig. S1). 
Unexpectedly, no known genes were shown to map to these 
regions. By LDI-PCR and LD-PCR, we found the exact 
breakpoints for four patients (P6, P12, P17, and P18;   Fig. 1 A  , 
Table S3, Fig. S1, and Fig. S2). 
  MiR-125b-1 is overexpressed in patients 
with the t(2;11) translocation 
  We next tested by quantitative RT-PCR (RQ-PCR) the 
status of genes/expressed sequence tags located around the 
breakpoint region (  THADA  ,   STS-1  ,   BRCC2  , and   MTA3  ) 
that could be deregulated in these pathologies, but we did 
not observe signifi  cant  modifi   cations of their expression 
(unpublished data). We focused our attention on the three 
microRNAs (miR-125b-1, let-7a-2, and miR-100) located 
near the breakpoint area on chromosome 11 (  Fig. 1 A  ). By 
RQ-PCR, we compared their level of expression in patients 
with the t(2;11) translocation with six patients with MDS 
and fi  ve patients with AML without the t(2;11) transloca-
tion. We also compared the results with three BM samples 
from healthy individuals. Among the 19 patients, mRNA 
was available for 6 MDS patients (P11, P12, P16, P17, P18, 
and P19) and for 5 AML patients (P3, P7, P8, P9, and P10). 
and Table S1, available at http://www.jem.org/cgi/content/
full/jem.20080285/DC1).   The median age of patients was 
60 yr. The MDS were classifi  ed as refractory cytopenia with 
multilineage dysplasia, refractory cytopenia with multilineage 
dysplasia with ring sideroblasts, and refractory anemia with 
excess blasts. The AMLs were classifi  ed in AML with multi-
lineage dysplasia in fi  ve patients or in AML evolving from 
myelodysplasia in three others. In two patients with AML, 
myelodysplastic signs could not be assessed. We can infer 
from these morphological data that AMLs with t(2;11) were 
acute phases of MDS in most patients. 
  The t(2;11) translocation was observed as a single abnor-
mality in 5 patients and associated with other changes in 14. 
Because the t(2;11) was found to be the only change, and 
because it was never observed as a secondary change, we can 
infer that this translocation was the primary change in all karyo-
types. In two patients, the normal chromosome 11 was lost 
and the derivative (  11  ) was duplicated, which reinforces the 
critical role of chromosome 11 in the translocation. The sec-
ondary abnormalities associated with the t(2;11) translocation 
were the most frequent changes reported in MDS: deletion 
of the long arm of chromosome 5, del(5q), in eight patients 
and chromosome 7 abnormalities in four others, either com-
plete monosomy 7 or partial deletion of the long arm, -7/
del(7q). Both del(5q) and -7 were found in one patient. There 
was no correlation between morphological and cytogenetic 
features, because the isolated t(2;11) was found both in AML 
and in MDS and because the complexity of karyotypes was 
similar in both hemopathies. Furthermore, in all patients di-
agnosed either as AML or MDS, the t(2;11) translocation was 
present in major clones, whereas normal metaphases were ei-
ther absent or present in minor cell populations, suggesting 
that the t(2;11) conferred a high proliferative advantage and 
was present in most dividing BM cells. Both morphological and 
cytogenetic data suggest that the t(2;11) translocation charac-
terizes a single genetic entity with the phenotype either of 
MDS or AML. 
  The breakpoints on chromosomes 2 and 11 cloned 
by fl  uorescent in situ hybridization (FISH), long-distance 
PCR (LD-PCR), and long-distance inverse PCR (LDI-PCR) 
do not involve candidate genes 
  Material for FISH was available in all cases, whereas molecu-
lar techniques were possible in only six cases.   MLL  , located 
on 11q23, was not involved in the t(2;11) translocation in 
this type of pathology. By FISH, we showed that the break-
point on chromosome 11 was located downstream from this 
gene (unpublished data). To determine the genes involved 
in this translocation, we progressively reduced the breakpoint 
regions on the two pathological chromosomes. The smallest 
interval was 10 megabases on chromosome 11. By FISH, us-
ing bacterial artifi  cial chromosome (BAC) probes, we showed 
that the breakpoint occurred in the same chromosomal re-
gions in all patients (  n   = 19;   Fig. 1 A  ; and Table S2, available 
at http://www.jem.org/cgi/content/full/jem.20080285/DC1). 
The BAC probe RP11-382J20 mapping on chromosome 11 
    Figure 2.         Overexpression of the mature miR-125b and one 
of its putative pri-microRNA (AK123947) in patients with the 
t(2;11)(p21;q23), as shown by RQ-PCR.   (A) Up-regulation of the ma-
ture miR-125b in fi  ve AML patients with the translocation (P3, P7, P8, P9, 
and P10) compared with controls (fi  ve cases of AML without the t(2;11) 
and three BM samples from healthy individuals; P   <   0.05). (B) The same 
results obtained in six MDS patients (P11, P12, P16, P17, P18, and P19). 
Controls are six MDS patients lacking the t(2;11) and three normal BM 
samples (P   <   0.05). (C) The putative pri-microRNA AK123947 is also up-
regulated in the AML patients (P3, P7, P8, and P9) compared with controls 
(P   <   0.05). (D) The same results obtained in MDS patients (P11, P12, P16, 
P17, and P18; P   <   0.05). Horizontal lines indicate mean values.     2502   MI R-125 B   AND MYELOID CELL TRANSFORMATION   | Bousquet et al. 
tients with the translocation compared with control cases 
(  Fig. 2, C and D  ). 
  MiR-125b overexpression signifi  cantly affects 
blast differentiation 
  The mechanisms accounting for miR-125b-1 up-regulation 
through the t(2;11)(p21;q23) translocation remain to be elu-
cidated. However, such a high level of expression implies 
that miR-125b-1 could play a pivotal role in the pathogene-
sis of subsets of MDS and AML. Of note, in addition to the 
t(2;11) translocation, 10 cases also had a deletion of the 5q31 
region. However, because there were some cases (  n   = 5) with 
isolated t(2;11), we suspected that this translocation was suffi   -
cient to interfere with the diff  erentiation of myeloid cells. 
These experiments showed an elevated expression of the 
miR-125b (from 6- to 90-fold) in patients with the trans-
location compared with healthy individuals, or individuals 
with MDS and AML lacking the t(2;11)(p21;q23) transloca-
tion (  Fig. 2, A and B  ).   However, the production of the ma-
ture miR-125b depends on two loci located on chromosomes 
11q23 and 21q21, and the RQ-PCR technique used did 
not allow discrimination between them. This prompted us 
to determine which could be the pri-microRNA of miR-
125b-1.   Fig. 1 A   indicates that many mRNAs could be at 
the origin of miR-125b-1. RQ-PCR confirmed that ma-
ture miR-125b was transcribed from chromosome 11 (miR-
125b-1 locus), because a strong expression of the mRNA 
AK123947 located on chromosome 11 was observed in pa-
    Figure 3.         Transient transfection with miR-125b blocks the differentiation of HL60 cells induced by DMSO.   (A  –  D) Changes in the morphology 
of May-Grunwald-Giemsa  –  stained cells (day 5): (A) HL60 cells electroporated with water (without DMSO), (B) HL60 cells electroporated with water (with 
DMSO), (C) HL60 cells electroporated with the microRNA negative control (with DMSO), and (D) HL60 cells electroporated with miR-125b (with DMSO). 
A representative experiment is shown. Bars, 5   μ  m. (E  –  H) Corresponding FACS experiments. A representative experiment is shown. (I) NSE staining. The 
data correspond to the mean from three independent experiments (P   <   0.05).     JEM VOL. 205, October 27, 2008  2503
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    Figure 4.         Transient transfection with miR-125b blocks the differentiation of NB4 cells induced by RA.   (A  –  D) Changes in morphology of 
May-Grunwald-Giemsa  –  stained cells (day 5): (A) NB4 cells electroporated with water (without RA), (B) NB4 cells electroporated with water (with RA), 
(C) NB4 cells electroporated with the microRNA negative control (with RA), and (D) NB4 cells electroporated with miR-125b (with RA). A representative 
experiment is shown. Bars, 5   μ  m. (E  –  H) Corresponding FACS experiments. A representative experiment is shown. (I) NBT staining. The data correspond 
to the mean from three independent experiments (P   <   0.05).     2504   MI R-125 B   AND MYELOID CELL TRANSFORMATION   | Bousquet et al. 
    Figure 5.         Transient transfection with miR-125b blocks the differentiation of CD34  +   primary cells.   (A  –  C) Differentiation was evaluated by cell 
morphology with May-Grunwald-Giemsa  –  stained cytocentrifuge slides after 8 d of differentiation induced by IL-3 and GM-CSF treatment and transient 
transfection (at day 5) with the negative control (A) or miR-125b (B). Bars, 5   μ  m. The proportion of immature cells (B) is higher upon miR-125b transfec-
tion than in controls (A). (C) Graphic representation of morphological data. The number of differentiated cells includes myelocytes, metamyelocytes, neu-
trophils, monocytes, and macrophages compared with the number of undifferentiated cells (blasts, myeloblasts, and promyelocytes). The data correspond 
to the mean of four independent experiments (P   <   0.05). (D) Corresponding CD11b expression by FACS analysis: primary blasts transfected with the nega-
tive control (blue, CD11b staining), and isotypic control [black] and primary blasts transfected with miR-125b (red, CD11b staining; green, isotypic control). 
A representative experiment is shown.     
To address this question, we tested whether, in transfection 
experiments, miR-125b was able to block the diff  erentiation 
of HL60 and NB4 leukemic cells upon chemical treatment. 
The experimental conditions allowed us to get a predomi-
nant maturation of HL60 into monocytic cells (after DMSO 
treatment), whereas NB4 cells treated with retinoic acid (RA) 
underwent characteristic granulocytic diff  erentiation. We ob-
served that in HL60 and NB4 cell lines, miR-125b was neither 
spontaneously up-regulated nor modulated during diff  erenti-
ation (unpublished data). After transient transfections, miR-
125b signifi  cantly prevented the diff  erentiation toward both 
lineages (  Figs. 3 and 4  ).   Regarding monocytic diff  erentia-
tion, the arrest of maturation was shown by both morphology 
(  Fig. 3, A  –  D  ) and reduced expression of CD14 in HL60 cells 
(  Fig. 3, E  –  H  ). These results were corroborated by those of 
the nonspecifi  c esterase (NSE) staining (  Fig. 3 I  ). Of note, it 
seemed that the blockage occurred between the expression of 
CD11b and CD14, i.e., in late stages of monocytic diff  erentia-
tion. As far as the granulocytic diff  erentiation was concerned, 
the acquisition of CD11b was clearly aff  ected by miR-125b 
transfection in NB4 cells upon RA treatment (  Fig. 4, E  –  H  ). 
The maturation blockage was confi  rmed by morphological 
analysis (  Fig. 4, A  –  D  ) and nitroblue tetrazolium (NBT) stain-
ing (  Fig. 4 I  ). 
  MiR-125b overexpression affects CD34  +   primary 
blast differentiation 
  Several experimental conditions were used to transfect pools 
(10  6   cells) of human CD34  +   primary blasts (four experi-
ments). The most signifi  cant eff  ect was seen in transient 
transfections, as described for leukemic cells (see Materials 
and methods). Taking into account the criteria applied to 
myeloid cells in vitro, the results obtained with primary 
blasts revealed a blockage of diff  erentiation that was par-
ticularly obvious with regard to morphological features. 
Roughly, we got half of diff  erentiated cells upon miR-125b 
transfection compared with controls (  Fig. 5, A  –  C  ).   This 
was evaluated 8 d after induction of diff  erentiation (upon 
GM-CSF treatment inducing both granulocytic and mono-
cytic diff  erentiation). Regarding the FACS results, in all 
experiments, there was a trend toward a delay in the acqui-
sition of CD11b (variations of 5  –  10%;   Fig. 5 D  ), but the 
  results did not exactly fi  t with the morphological features 
seen for leukemic cells. This clearly suggests that the eff  ect 
of miR-125b is greatly dependent on the stage and the path-
way of diff  erentiation of targeted cells. As seen in HL60 cells 
(with monocytic diff  erentiation), miR-125b less signifi  cantly 
aff  ected CD11b expression than in NB4 cells (upon granulo-
cytic maturation). JEM VOL. 205, October 27, 2008  2505
BRIEF DEFINITIVE REPORT
  We report herein the fi  rst chromosomal translocation up-
regulating a microRNA in MDS and AML. The targeted 
microRNA miR-125b is capable of blocking the myelo-
monocytic diff  erentiation of cell lines in vitro, a previously 
unknown function. Therefore, miR-125b up-regulation repre-
sents another mechanism of myeloid cell transformation that 
could be used as a diagnostic marker and therapeutic target in 
subsets of MDS and AML. 
  MATERIALS AND METHODS 
  Patient material.     Cohorts studied included patients collected by the Labora-
tory of Hematology Cytogenetics, Centre Hospitalier Universitaire Purpan, and 
the Cytogenetic and Molecular Genetic Unit, Division of Hematology, IBiT 
Foundation, University of Perugia. French (reference: code Fran  ç  ais de la sant  é   
publique Art.1.1211-2 alinea 2C) and Italian laws are similar and do not require 
consent for genetic analyses for dead or lost to follow-up patients. All patients 
enrolled (  n   = 19) were dead or lost to follow-up at the beginning of this study. 
  FISH.     BAC and fosmid clones were obtained from the Welcome Trust Sanger 
Institute (http://www.sanger.ac.uk). DNA was labeled with biotin-16-dUTP 
or digoxigenin-11-dUTP (Roche), using a nick translation kit (GE Healthcare) 
according to the manufacturer  ’  s instructions. 
  LDI-PCR.     DNA was digested with   PstI   or   ApaI   and purifi  ed by standard 
  methods. The DNA was diluted to a concentration of 1 ng/  μ  l and incubated at 
14  °  C overnight in the presence of 1 U   T4   DNA ligase. The self-ligated circular 
DNA was used as a template in PCR experiments using the Advantage 2 PCR 
enzyme system (BD Biosciences) and primers listed in Table S3. Nucleotide se-
quencing of PCR products was performed with the ABI Prism Dye Terminator 
kit (PerkinElmer and Applied Biosystems). 
  RQ-PCR on microRNAs.     RT was performed for each microRNA us-
ing the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosys-
tems) according to the manufacturer  ’  s instructions. Quantitative PCR was 
performed on an ABI7300 (Applied Biosystems) using TaqMan Micro-
RNA Assays (Applied Biosystems). The data presented correspond to the 
mean of 2              Ct   from three independent reactions, normalized to the   RNU43   
reference gene. 
  RQ-PCR on mRNAs.     cDNA was synthesized using M-MLV RT (Invit-
rogen) according to the manufacturer  ’  s instructions. Quantitative PCR was 
performed on an ABI7300 using qPCR MasterMix Plus for SYBR green 
(Eurogentec). AKf (5    -AGCTCAACGGAGGATTGTGCC-3    ) and AKr 
(5    -TCAGTCTTTGTCCTTGCACTGG-3    ) primers were used to am-
plify the   AK123947   cDNA. The data presented correspond to the mean of 
2              Ct   from three independent reactions, normalized to the   MLN51   and 
  ACTIN   reference genes. 
  Cell lines and treatments.     The HL60 and NB4 cell lines were cultured, 
respectively, in IMDM (Invitrogen) supplemented with 20% fetal bovine se-
rum and in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal 
bovine serum,   l  -glutamine, penicillin, and streptomycin. 
  Transient transfections were performed on 3   ×   10  6   HL60 and NB4 cells 
with 22.5   μ  l of Pre-miR miRNA Precursor-miR-125b (50   μ  M), Pre-miR 
miRNA Precursor-Negative control #1 (50   μ  M; Applied Biosystems), or 
H  2  O by electroporation at 950   μ  F and 280 V. After 24 h, HL60 and NB4 
cells were diff  erentiated into monocytes by treatment with 1.25% DMSO 
(Sigma-Aldrich) and into granulocytes with 1   μ  M RA (Sigma-Aldrich), re-
spectively, for 5 d. 
  CD34  +   primary blasts (StemCell Technologies Inc.) were cultured in 
IMDM medium supplemented with 10% fetal bovine serum, penicillin, strepto-
mycin, 50 ng/ml stem cell factor, 50 ng/ml FLT-3 Ligand, 10 ng/ml IL-3, and 
50 ng/ml GM-CSF. Transient transfections were performed on 10  6   cells, after 
5 d of diff  erentiation, with 7.25   μ  l of Pre-miR miRNA Precursor-miR-125b 
  Among the candidate microRNAs located at fragile sites, 
in particular at 11q23, miR-125b-1 has been already re-
ported, but its direct implication still remained hypothetical 
(  7  ). A sporadic case of B acute lymphoblastic leukemia with 
a chromosomal translocation that rearranged miR-125b-1 
with the IgH locus was reported, but no quantitative experi-
ments were performed to determine whether this microRNA 
was deregulated (  11  ). MiR125-b is critical in diff  erent pro-
cesses of cell proliferation and diff  erentiation, but most of 
the knowledge about its functions has been obtained from 
studies on its putative homologue   lin-4   in   Caenorhaditis ele-
gans   (  12  ). In particular, mutations in lin-4 are associated with 
developmental defects (  10, 12, 13  ). The potential targets of 
miR-125b are listed in Table S4 (available at http://www
.jem.org/cgi/content/full/jem.20080285/DC1). Because this 
microRNA has not been extensively studied, descriptions of 
target genes involved in hematopoietic diff  erentiation are 
rare. We used a bioinformatic approach based on the combi-
nation of the four main softwares available to date (TargetScan, 
RNAhybrid, PicTar, and miRanda). Among the list of pu-
tative targets of miR-125b,   MLF2   (myelodysplasia/myeloid 
leukemia factor 2) and   MCL1   (myeloid cell leukemia 1) 
look promising. 
  The role of several microRNA sets in the molecular mech-
anisms that control myelomonocytic cell proliferation and dif-
ferentiation has been documented (  5, 14  –  18  ). In a very recent 
paper (  15  ), the authors demonstrated a strong repression of the 
myelopoiesis regulator miR-223 by the AML1/ETO chimeric 
protein in AML. In the latter study, the molecular event was 
an epigenetic silencing of that microRNA. It is noteworthy 
that in normal conditions miR-223 promotes myeloid cell dif-
ferentiation (  15, 16  ). In the cases with the t(2;11) translocation, 
there is an up-regulation of miR-125b, which is directly linked 
to the chromosomal changes. In addition, miR-125b acts in an 
opposite direction by blocking the process of diff  erentiation. 
This is a novel and so far unknown function for miR-125b. 
  In the study by Garzon et al., 60 untreated AML patients 
were tested for microRNA transcription profi  les (  19  ). A small 
subset of microRNAs correlated with survival, and some of 
them were associated with cytogenetic and molecular abnor-
malities (  19  ). 8 microRNAs were up-regulated and 14 were 
down-regulated in cases with 11q23 balanced translocations. 
However, these profi  les corresponded to cases with t(6;11) or 
t(9;11) translocations, usually involving the   MLL   gene. The 
fact that, in the latter study (  19  ), miR-125b was not identifi  ed 
as a target strongly suggests that the up-regulation observed 
in our patients is specifi  c to the t(2;11) translocation. This 
conclusion is reinforced by the very high level of expression 
(from 6- to 90-fold) of miR-125b-1 in tumor cells carrying the 
t(2;11) translocation. To strengthen the hypothesis that miR-
125b is a key player in myeloid cell disorders, we retrieved 
cases with chromosomal abnormalities involving 21q21-22 
(the region containing miR-125b-2). Interestingly, in one pa-
tient with AML, we observed that miR-125b-2 was strongly 
up-regulated (x450; Fig. S3, available at http://www.jem.org/
cgi/content/full/jem.20080285/DC1). 2506   MI R-125 B   AND MYELOID CELL TRANSFORMATION   | Bousquet et al. 
(50   μ  M) or Pre-miR miRNA Precursor-Negative control #1 (50   μ  M) by elec-
troporation using the human CD34 cell nucleofector kit (Amaxa Biosystems). 
  Evaluation of myeloid diff  erentiation.     Monocytic diff  erentiation was 
evaluated by cell morphology with May-Grunwald-Giemsa  –  stained cytocen-
trifuge slides, NSE staining as previously described (  20  ), and expression of 
CD11b and CD14. Granulocytic diff  erentiation was evaluated by cell mor-
phology with May-Grunwald-Giemsa  –  stained cytocentrifuge slides, NBT 
(provided by C. Chomienne, St. Louis Hospital Paris, Paris, France) reduc-
tion activity as previously described (  21  ), and expression of CD11b and 
CD15. CD34  +   primary blast diff  erentiation was evaluated by cell morphol-
ogy with May-Grunwald-Giemsa  –  stained cytocentrifuge slides and expres-
sion of CD11b (FACS). 300 cells were counted in each reaction (NSE, NBT, 
and morphology). For fl  ow cytometry staining, the following anti  –  human 
monoclonal antibodies (provided by J.J. Fourni  é  , Institut National de la Sant  é   
et de la Recherche M  é  dicale, Toulouse, France) were used: CD11b-PE-Cy7 
(1:100; BD Biosciences), CD14-PE-Cy5 (1:50; Beckman Coulter), and 
CD15-FITC (1:30; BD Biosciences). Flow cytometry analysis was performed 
using a fl  ow cytometer (LSRII; BD Biosciences), and data were analyzed 
with FACSDiva software (BD Biosciences). A minimum of 10,000 events 
were collected for each sample. 
  Statistical analysis.     For RQ-PCR experiments, the diff  erent groups were 
compared by a Kruskal-Wallis test. For NSE, NBT, and morphological anal-
yses, the Mann-Whitney test was used. P   <   0.05 was considered signifi  cant. 
  Online supplemental material.     In Table S1, clinical data and com-
plete karyotypes of the 19 patients are listed. In Table S2, results of FISH 
in all patients are shown. In Table S3, primers used in LDI-PCR experi-
ments are listed. In Table S4, putative targets of miR-125b are listed. Fig. S1 
describes breakpoint regions on chromosome 2 and shows FISH experi-
ments on chromosome 2. Fig. S2 shows chromatograms of the breakpoint 
regions in four patients obtained by LDI-PCR or LD-PCR. Fig. S3 shows an 
up-regulation of miR-125b in a case of AML with amplifi  cation at 21q. 
Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20080285/DC1. 
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